Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 3/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092215 | 1.00 | FOLH1 (0.44) | FOLH1ACELMNAALKBH5SUCNR1 | |
| SCHEMBL30505307 | 1.00 | FOLH1 (0.44) | FOLH1ACELMNAALKBH5SUCNR1 | |
| SCHEMBL39838 | 1.00 | FOLH1 (0.44) | FOLH1ACELMNAALKBH5SUCNR1 | |
| SCHEMBL13907082 | 1.00 | FOLH1 (0.44) | FOLH1ACELMNAALKBH5SUCNR1 | |
| SCHEMBL6366305 | 0.97 | — | — | |
| SCHEMBL15907907 | 0.88 | FOLH1 (0.42) | FOLH1ACELMNAALKBH5SUCNR1 | |
| Mercaptopropionic Acid SCHEMBL331255 | 0.87 | ACE (0.50) | FOLH1ACELMNAALKBH5SUCNR1 | |
| SCHEMBL1766170 | 0.87 | LMNA (0.50) | LMNAALKBH5SUCNR1EGLN1PMP22 | |
| SCHEMBL351356 | 0.87 | LMNA (0.50) | LMNAALKBH5SUCNR1EGLN1PMP22 | |
| SCHEMBL1766162 | 0.87 | LMNA (0.50) | LMNAALKBH5SUCNR1EGLN1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240772-B1 | FUNCTIONALISED BIOCHIPS FOR SPR-MS COUPLING | GENOPTICS (FR) | 2016-09-07 | — | — | EP | claimed |
| US-12638449-B2 | Methods and related aspects for detecting unlabeled biomolecules | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250237609-A1 | CHARGE-SENSITIVE OPTICAL DETECTION OF BINDING KINETICS BETWEEN PHAGE DISPLAYED PEPTIDE LIGANDS AND PROTEIN TARGETS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-07-24 | — | — | US | disclosed |
| US-12259330-B2 | Charge-sensitive optical detection of binding kinetics between phage displayed peptide ligands and protein targets | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240376169-A1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | WASHINGTON UNIVERSITY | 2024-11-14 | — | — | US | disclosed |
| US-20240272082-A1 | CHARGE-SENSITIVE OPTICAL DETECTION OF BINDING KINETICS BETWEEN PHAGE DISPLAYED PEPTIDE LIGANDS AND PROTEIN TARGETS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4382535-A2 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | Washington University (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240118200-A1 | CRITICAL ANGLE REFLECTION IMAGING FOR QUANTIFICATION OF MOLECULAR INTERACTIONS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-04-11 | — | — | US | disclosed |
| EP-3875152-B1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | WASHINGTON UNIVERSITY ST LOUIS (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11938193-B2 | Compositions comprising chemerin and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2024-03-26 | — | — | US | disclosed |
| EP-2591354-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109604-A1 | LOW VISCOSITY LUBRICATING OIL BASE STOCKS AND PROCESSES FOR PREPARING SAME | EXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20110144163-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | ZAHAV BIOSCIENCES LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110144163-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | ZAHAV BIOSCIENCES LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110045180-A1 | METHOD OF MANIPULATING THE SURFACE DENSITY OF FUNCTIONAL MOLECULES ON NANOPARTICLES | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (HK) | 2011-02-24 | — | — | US | disclosed |
| EP-2217063-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | Virginia Tech Intellectual Properties, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009062138-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12638449-B2 | Methods and related aspects for detecting unlabeled biomolecules | EPCAM, CD63, CD47 | FOLH1 278/4885ACE 936/4885LMNA 124/4885 |
| US-20110144163-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | TUBB6, TUBB1, TUBB | FOLH1 682/4885ACE 3210/4885LMNA 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.